The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized phase III trial of amrubicin versus topotecan (Topo) as second-line treatment for small cell lung cancer (SCLC).
R. Jotte
No relevant relationships to disclose
J. Von Pawel
No relevant relationships to disclose
D. R. Spigel
Consultant or Advisory Role - Celgene (U)
M. A. Socinski
Honoraria - Genentech; Lilly
Research Funding - Celgene; Genentech; Lilly; Pfizer; Synta
M. O'Brien
Consultant or Advisory Role - Celgene
Honoraria - Celgene
Research Funding - Celgene
E. H. Paschold
No relevant relationships to disclose
J. Mezger
No relevant relationships to disclose
M. Steins
No relevant relationships to disclose
L. Bosquée
No relevant relationships to disclose
J. A. Bubis
Honoraria - Celgene
K. Nackaerts
No relevant relationships to disclose
J. M. Trigo Perez
No relevant relationships to disclose
P. R. Clingan
No relevant relationships to disclose
W. Schuette
No relevant relationships to disclose
P. Lorigan
No relevant relationships to disclose
M. Reck
Consultant or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Lilly; Pfizer; Roche
Honoraria - AstraZeneca; Lilly; Roche
M. Domine
No relevant relationships to disclose
F. A. Shepherd
Consultant or Advisory Role - Celgene
R. McNally
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
M. F. Renschler
Employment or Leadership Position - Celgene
Stock Ownership - Celgene